Skip to main content
. 2021 Sep 28;76:e3146. doi: 10.6061/clinics/2021/e3146

Table 2. Radiological response in the intention-to-treat population with advanced hormone-receptor positive breast cancer treated with anti-Lewis Y monoclonal antibody (hu3S193).

No. of patients (N=21) %
Complete response 0 0
Partial response 0 0
Stable disease (SD)
SD as best radiological response 12 57.1%
SD confirmed after 24 weeks 4 19%
Disease progression (as best radiological response) 8 38.1%
Not evaluable* 1 4.8%

Abbreviations: No., number; SD, stable disease.

*

One patient presented with clinical worsening in the first weeks of treatment and did not undergo imaging evaluation after treatment.